Arrowhead Pharmaceuticals, Inc. Stock News

Arrowhead Pharmaceuticals, Inc. ( ARWR ) TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 24, 2025 1:30 PM EST Company Participants James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Everyone, and thank you for joining us at TD Cowen's...

The biotech published its latest set of annual results. It's now got several revenue streams that are already significantly boosting the fundamentals.

Arrowhead Pharmaceuticals, Inc. ( ARWR ) Q4 2025 Earnings Call November 25, 2025 4:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise James Hamilton - Chief Medical Officer and Head of R&D Daniel Apel - Chief F...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results. “The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with fami...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference (RNAi) ...

Arrowhead Pharmaceuticals, Inc. ( ARWR ) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome November 18, 2025 1:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Bruce Given - Chief Medical Scientist Andy Da...

FDA approved Plozasiran (now REDEMPLO™) on November 18, 2025, for reducing triglycerides in adults with FCS, the first siRNA therapy for this rare disease. ARWR boasts a diversified RNAi pipeline targeting liver, lung, muscle, CNS, and obesity, with multiple late-stage candidates and strong efficacy data. The company maintains a robust cash runway of 24 months, supported by partnerships and mil...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 peopl...